Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received an average recommendation of "Buy" from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $66.67.

Several equities analysts recently commented on the stock. Guggenheim increased their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target for the company in a research report on Tuesday, May 27th. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 price target for the company. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research report on Monday, May 5th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Summit Investment Advisors Inc. boosted its holdings in Tarsus Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after acquiring an additional 244 shares in the last quarter. Amalgamated Bank raised its position in shares of Tarsus Pharmaceuticals by 30.1% in the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after purchasing an additional 295 shares during the last quarter. Sherbrooke Park Advisers LLC boosted its stake in Tarsus Pharmaceuticals by 7.2% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company's stock worth $364,000 after purchasing an additional 443 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth about $25,000. Finally, Arizona State Retirement System grew its position in Tarsus Pharmaceuticals by 6.1% during the 1st quarter. Arizona State Retirement System now owns 8,182 shares of the company's stock valued at $420,000 after purchasing an additional 470 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $39.18 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.54 and a current ratio of 5.57. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The firm's fifty day moving average is $42.36 and its 200 day moving average is $47.07. The firm has a market cap of $1.65 billion, a P/E ratio of -14.35 and a beta of 0.80.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Research analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.